9-5-1: The investigational intervention is an oral food-supplement capsule combining curcumin, ginger, and piperine in a proprietary "9-5-1" ratio (curcuma extract : ginger extract : black pepper/piperine extract), administered as 4 capsules per day for 30 consecutive days prior to the race.
Placebo: Capsule excipients are maltodextrin and hydroxypropylmethylcellulose (HPMC), allowing an identical-appearing placebo for double-blind conditions.
Study summary
ECUM-RUN is a randomized, double-blind, placebo-controlled phase 3 trial evaluating whether a 30-day oral supplementation with curcumin, ginger, and piperine (9-5-1 formulation) reduces exercise-induced joint pain and inflammatory markers in 82 ultra-trail runners competing in the Diagonale des Fous (175 km). The primary endpoint is the change in knee pain (VAS score) between end of supplementation and race finish, compared between intervention and placebo groups.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
* Age ≥ 18 years at inclusion
* Registered for "La Diagonale des Fous" (Grand Raid de La Réunion, 175 km, 2026 edition)
* Free, informed, signed consent obtained prior to any study-related procedure
* Availability to participate in the full protocol, including preliminary consultations and biological sampling at all time points (T0 to T3)
* Affiliated with or beneficiary of a social security scheme
* Ability to understand and follow study instructions (sufficient French language level, or assistance available)
Exclusion Criteria:
* Regular NSAID use in the 30 days prior to inclusion, defined as intake at least 3 days/week for at least 2 consecutive weeks, or ongoing treatment at the time of inclusion
* Regular use of curcumin-containing supplements or "9-5-1"-type preparations in the 30 days prior to inclusion, defined as intake at least 3 days/week for at least 2 consecutive weeks
* Taking anticoagulant treatment
* History of hepatic, biliary, or pancreatic disease, including: gallstones, cholestasis, acute or chronic hepatitis, cirrhosis
* Known allergy or documented hypersensitivity to any capsule component: turmeric, curcumin, ginger, black pepper, maltodextrin, or hydroxypropylmethylcellulose (HPMC)
* Chronic inflammatory joint disease (e.g., rheumatoid arthritis, spondyloarthritis) under active specific treatment
* Pregnancy or breastfeeding
* Participation in another biomedical study involving a therapeutic intervention within the 30 days prior to inclusion
* Severe cognitive or psychiatric impairment preventing understanding of the protocol or completion of questionnaires
* Patient under guardianship/curatorship or subject to a legal protection order
Primary outcome measure(s)
Change in Knee Pain Intensity from End of Supplementation to Race Finish (Visual Analog Scale) — From Day 30 (T1, end of the 30-day supplementation period) to race finish or withdrawal (T2) - up to approximately 60 hours later, corresponding to the maximum allowed race duration. Knee pain is self-assessed using a Visual Analog Scale (VAS, 0-10 cm) at the end of the 30-day supplementation period (T1, day before the race) and immediately at race finish or withdrawal (T2). The primary outcome is the within-participant change in VAS score (T2 minus T1), compared between the curcumin-ginger-piperine (9-5-1) group and the placebo group.
Trial sites (1)
Facility
City
Region
Status
Dr Nicolas BOUSCAREN
Saint-Pierre
CHU de La Réunion
Recruiting
More Centre Hospitalier Universitaire de la Réunion trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
